COMMUNIQUÉS West-GlobeNewswire

Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services
28/02/2026
BEIJING, Feb. 28, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has signed a strategic collaboration agreement with [...]
Sugar Harmony Drops Claims Evaluated: 2026 Report on SugarHarmony Liquid Formula Ingredients, Pricing, and What Consumers Should Verify Before Purchasing
28/02/2026
A 2026 informational consumer evaluation of Sugar Harmony Drops marketing claims, ingredient research context, liquid supplement format considerations, pricing structure, and what consumers should verify before [...]
Zealthy Hydroquinone 2026: Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment
28/02/2026
An informational consumer overview of Zealthy's prescription hydroquinone program, including compounded medication status, FDA context, telehealth dermatology consultation details, subscription and refund terms, side [...]
Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations): Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting
28/02/2026
Informational consumer guide examines Zealthy's online ED treatment model, sublingual Hardies formulations, provider evaluation process, subscription structure, and compounded medication disclosures for men evaluating [...]
ReduBurn Thermogenic Resistance Claims Evaluated: Latest Report on Ingredients, Pricing, Refund Terms, and What Consumers Should Verify Before Buying
28/02/2026
Informational 2026 customer report evaluates ReduBurn marketing claims, ingredient transparency, thermogenic resistance framing, pricing structure, published refund terms, and consumer due diligence for men and women. [...]
BreezeMeds GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Pricing (From $199), FDA Regulatory Status Examined
28/02/2026
A 2026 Informational Overview of the BreezeMeds Compounded GLP-1 Telehealth Weight Loss Platform, Semaglutide and Tirzepatide Medication Formats, Published Pricing Structure, 503A Compounding Pharmacy Framework, [...]
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
27/02/2026
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing [...]
Publication relating to transparency notifications
27/02/2026
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), February 27, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]
OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
27/02/2026
CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC: OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the [...]
LeMaitre to Participate at Upcoming Investor Conferences in March
27/02/2026
BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March. Leerink Partners Global [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
27/02/2026
ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]
Weight Watchers Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call
27/02/2026
NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December 31, 2025 before [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
27/02/2026
Company Announcement COPENHAGEN, Denmark; February 27, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
27/02/2026
WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
27/02/2026
Company Announcement COPENHAGEN, Denmark; February 27, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 587,495 restricted stock units to members of management and employees [...]
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
27/02/2026
WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) [...]
Publication relative à des notifications de transparence
27/02/2026
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 27 février 2026 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative [...]
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
27/02/2026
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
27/02/2026
The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval Commercial availability expected during early part of Q2 2026 Rare Pediatric Disease [...]

Pages